BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

Adult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care

Trial Details

NCT ID

NCT06441890

Phase

PHASE2

Sponsor

University of Illinois at Chicago

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

Paclitaxel
Nab-paclitaxel
Docetaxel
Trastuzumab
Pertuzumab

Locations (sample)

Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

Age ≥ 18 years of age at time of consent
ECOG performance status 0, 1, or 2
Histologically confirmed invasive breast cancer documented by core needle or surgical biopsy with 90 days prior to study registration.
HER2-positive by IHC or FISH according to ASCO/CAP 2018 guidelines

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →